Business Wire

GIGA-CARBON-NEUTRALITY

11.11.2021 09:54:11 CET | Business Wire | Press release

Share
Clean Energy Trucking Company Giga Carbon Neutrality Is Preparing to Launch 21 Zero-emission Commercial Vehicles by the End Of 2023

Giga Carbon Neutrality (GCN), the clean trucking and technology company, today unveiled a comprehensive range of zero-emission commercial vehicles that it plans to bring to market over the next two years – answering the call from the world’s transportation and logistics operators for a fleet of different options.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005555/en/

GCN will launch 21 different battery-electric and hydrogen fuel-cell powered vehicles by the end of 2023. GCN’s portfolio is configurable to a wide range of commercial use cases and includes a tractor unit, buses and last-mile logistics vehicles. The company’s first prototype hydrogen-fueled tractor unit is currently undergoing advanced road and usability trials in China.

GCN designs its vehicles at a state-of-the-art research and development centre located in Hangzhou , China. GCN has developed its own proprietary hydrogen fuel-cell technology and will source batteries from leading manufacturers initially.

The GCN vehicles are manufactured using lightweight stainless steel and composite materials to improve safety and deliver reductions in weight and energy consumption of at least 10 per cent. The bodies of GCN vehicles are designed to last for 20 years, significantly longer than vehicles from other providers on the market.

GCN is working with public and private sector partners to provide clean energy storage, charging and refueling infrastructure, as well as specialist financing to support the adoption of its zero-emission commercial vehicles globally.

Marty Wade, CEO at Giga Carbon Neutrality, comments: “We are thrilled to give the world its first look at the future of zero-emission commercial transportation.”

“GCN is enabling a carbon-neutral future for some of the world’s most energy-intensive industries, with clean energy vehicles, new technologies and a fueling ecosystem to make running clean, reliable vehicle fleets easy for commercial transportation companies.”

Giga’s initial fleet of zero-emission commercial vehicles

Several GCN vehicles are available to order immediately, with delivery times of between three and 12 months. The company’s initial range includes:

  • The GCN Hydrogen Tractor: A 44-tonne hydrogen fuel-cell truck with a top speed of 90 kph and 580 km range before refueling. Streamlined to minimise wind-resistance, GCN’s ‘heavy truck’ features an ergonomic cab design and a range of intelligent safety systems such as driver fatigue warning systems as standard. A prototype of this vehicle is already on the road in China.
  • The GCN City Bus: A 12-metre transit bus for urban public transport. Capable of carrying up to 95 passengers, GCN’s city bus has a 350 km range on a battery-electric power train and features a monocoque body and collision protection structure offering improved safety for the driver and passengers. This vehicle is designed to meet European Union approved standards for use in its 27 member states.
  • The GCN Pure Electric Minibus: A 6.9-metre battery-electric minibus with an ultra-long wheelbase and flat floor structure to provide capacity for up to 13 passengers. GCN’s minibuses have a 240 km range on a single charge and are already being used on the road in Hong Kong. Autonomous vehicles can also be developed based on this platform.
  • The GCN Electric Logistics Vehicle: An 8-tonne battery-electric truck to support last-mile logistics in urban and rural areas. GCN’s logistics truck has a spacious loading area, can be configured to customer needs and can cover 250 km on a single charge.

About Giga Carbon Neutrality (www.gigacarbonneutrality.com )

Giga Carbon Neutrality is a clean energy trucking and technology company with a supporting ‘Energy-as-a-Service’ (EaaS) offering that makes running clean, reliable vehicle fleets easy for industrial and commercial transportation companies. GCN'S portfolio includes battery-electric and hydrogen fuel cell vehicles, clean energy storage, charging and refueling infrastructure, and specialist financing to support the transition to zero-emission vehicles.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye